2 1 Shi Ji Jing Ji Bao Dao·2025-06-09 02:20Group 1 - The A-share market indices experienced a collective upward trend, with the STAR Market Biopharmaceutical Index showing significant strength [1] - The STAR Market Biopharmaceutical Index ETF (588700) rose by 2.25%, with a trading volume exceeding 18 million yuan and a turnover rate of 7.97%, indicating active trading [1] - Key constituent stocks such as Yuyuan Pharmaceutical, Shouyao Holdings-U, and Nuotai Bio saw increases of over 7% [1] Group 2 - Harvard University's Belfer Center report indicates that China has a strong opportunity to surpass the U.S. in biotechnology, particularly in drug development [2] - The report highlights that while the U.S. leads in five key technology areas, the gap in biotechnology is narrowing, with China emerging as a source of original innovation [2] - CITIC Securities notes that the American Society of Clinical Oncology (ASCO) annual meeting is the largest and most authoritative clinical oncology conference, with increasing representation of domestic innovative drug data [2] Group 3 - Century Securities reports that there are ongoing developments in the innovative drug sector, particularly with the collaboration between Bristol-Myers Squibb and BioNTech for a $9 billion joint development of a PD-L1/VEGF dual antibody [3] - The ASCO meeting showcased significant progress in dual antibodies and ADC fields, with new mechanisms and targets emerging, indicating a differentiated layout in early clinical stages [3] - The competitiveness of domestic innovative drug pipelines on a global scale is expected to continue to rise, with a long-term positive outlook on the international expansion of innovative drugs [3]